A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.

Animals CD40 Antigens / antagonists & inhibitors CD40 Ligand / chemistry Drug Administration Schedule Drug Evaluation, Preclinical Encephalomyelitis, Autoimmune, Experimental / drug therapy Female Immunologic Memory Mice Mice, Inbred C57BL Oligopeptides / administration & dosage T-Lymphocyte Subsets / drug effects
CD154 CD40 EAE Therapeutic peptide

Journal

Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 12 02 2019
revised: 15 03 2019
accepted: 20 03 2019
pubmed: 30 3 2019
medline: 31 3 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

CD40/CD154-interaction is critical in the development of Experimental Autoimmune Encephalomyelitis (EAE; mouse model of Multiple Sclerosis). Culprit CD4

Identifiants

DOI: 10.1016/j.jneuroim.2019.03.013 PMID: 30925295 PMC: PMC6535109
pubmed: 30925295
pii: S0165-5728(19)30063-3
doi: 10.1016/j.jneuroim.2019.03.013
pmc: PMC6535109
mid: NIHMS1525670
pii:
doi:

Substances chimiques

CD40 Antigens 0
Oligopeptides 0
CD40 Ligand 147205-72-9

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-15

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK131196
Pays : United States
Organisme : NIAID NIH HHS
ID : R41 AI113977
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR057212
Pays : United States
Organisme : NIDDK NIH HHS
ID : R42 DK115296
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

J Immunol. 1999 Apr 15;162(8):4490-5
pubmed: 10201986
J Exp Med. 2001 Sep 3;194(5):669-76
pubmed: 11535634
J Autoimmun. 2002 Mar;18(2):83-94
pubmed: 11908941
Invest New Drugs. 2002 May;20(2):209-19
pubmed: 12099581
Arthritis Rheum. 2003 Mar;48(3):719-27
pubmed: 12632425
APMIS. 1992 Apr;100(4):287-93
pubmed: 1374617
Eur J Immunol. 2004 May;34(5):1488-97
pubmed: 15114683
Lupus. 2004;13(5):391-7
pubmed: 15230298
Autoimmunity. 2004 Sep-Nov;37(6-7):457-64
pubmed: 15621572
Mod Rheumatol. 2005;15(6):423-6
pubmed: 17029106
J Immunol. 2007 Jan 15;178(2):671-82
pubmed: 17202327
Autoimmun Rev. 2007 Jan;6(3):169-75
pubmed: 17289553
J Neuroimmunol. 2008 Mar;195(1-2):1-6
pubmed: 18177950
Curr Opin Mol Ther. 2008 Oct;10(5):516-25
pubmed: 18830927
J Autoimmun. 2008 Dec;31(4):385-92
pubmed: 18951762
Biochem Pharmacol. 2009 Apr 1;77(7):1236-45
pubmed: 19283894
Semin Immunol. 2009 Oct;21(5):293-300
pubmed: 19595612
J Mol Med (Berl). 2009 Nov;87(11):1133-43
pubmed: 19707732
J Neuroimmune Pharmacol. 2010 Jun;5(2):189-97
pubmed: 20107924
Curr Protoc Immunol. 2010 Feb;Chapter 15:Unit 15.1
pubmed: 20143314
Mol Immunol. 2010 Aug;47(14):2303-13
pubmed: 20646763
Clin Exp Immunol. 2010 Oct;162(1):1-11
pubmed: 20682002
BJOG. 2011 Oct;118(11):1349-56
pubmed: 21668768
Expert Rev Neurother. 2012 Apr;12(4):371-84
pubmed: 22449210
PLoS One. 2012;7(6):e38708
pubmed: 22685601
J Neuroimmunol. 2013 Jul 15;260(1-2):60-73
pubmed: 23622820
Expert Opin Ther Targets. 2013 Sep;17(9):1053-66
pubmed: 23829711
Cell Mol Immunol. 2013 Nov;10(6):483-9
pubmed: 24037181
Diabetologia. 2014 Nov;57(11):2366-73
pubmed: 25104468
J Immunol. 2015 Mar 1;194(5):2059-63
pubmed: 25624457
Arthritis Res Ther. 2015 Sep 03;17:234
pubmed: 26335795
Clin Immunol. 2017 Feb;175:10-15
pubmed: 27890706
Immunity. 2017 Jan 17;46(1):120-132
pubmed: 28087238
PLoS One. 2017 Feb 13;12(2):e0172037
pubmed: 28192476
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
Immunology. 2017 Oct;152(2):243-254
pubmed: 28542921
Behring Inst Mitt. 1993 Aug;(92):165-77
pubmed: 7504448
Biochemistry. 1995 Feb 14;34(6):1833-44
pubmed: 7531493
Biochemistry. 1995 Aug 8;34(31):9884-92
pubmed: 7543281
Curr Opin Immunol. 1993 Oct;5(5):747-52
pubmed: 7694594
Science. 1996 Apr 5;272(5258):60-6
pubmed: 8600538
J Immunol. 1997 Aug 15;159(4):1686-94
pubmed: 9257829
J Clin Invest. 1999 Jan;103(2):281-90
pubmed: 9916140

Auteurs

Gisela M Vaitaitis (GM)

Webb-Waring Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: gisela.vaitaitis@ucdenver.edu.

Martin G Yussman (MG)

Webb-Waring Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: martin.yussman@ucdenver.edu.

David H Wagner (DH)

Webb-Waring Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: david.wagner@ucdenver.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD40 › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Ligand de CD40 › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Calendrier d'administration des médicaments › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Maladie neurologique auto-immune expérimentale › Encéphalomyélite auto-immune expérimentale › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Mémoire immunologique › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › A CD40 targeting peptide prevents severe...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › A CD40 targeting peptide prevents severe...